--- a
+++ b/clusters/9knumclustersv2/clust_1495.txt
@@ -0,0 +1,16 @@
+Previous treatment with regorafenib AND TAS- (this applies to phase II only; if patients have previously received either regorafenib OR TAS-, they must be able to receive the alternate regimen if randomized to the standard of care arm)
+Prior treatment with TAS-
+Participants who have previously received TAS-
+Previous use of TAS-, S-, and -FU drugs;
+Prior therapy with TAS-
+Contraindications to TAS-\r\n* Absolute neutrophil count < ,/ul\r\n* Platelet count < ,/ul\r\n* Allergy or intolerance to TAS-
+Any medication administered within  weeks prior to st dose of TAS that is known to affect QT interval or arrhythmogenic
+Received prior treatment of TAS
+Has known hypersensitivity to TAS- or its components.
+Prior treatment with TAS- or regorafenib
+Prior MEK inhibitor or prior TAS- therapy
+Previous treatment with TAS- or TMZ
+Has previously received TAS-.
+Any of the following treatments, within the specified time frame, prior to the first dose of TAS:
+Prior treatment with TAS or known hypersensitivity to any of its inactive ingredients or drugs similar in class
+Known sensitivity to TAS-, CPT-, Bevacizumab, or their components